- Chronic Lymphocytic Leukemia:
- 100mg/m² IV infusion on days 1 and 2 of 28-day cycle, repeated for up to 6 cycles
- Infuse over 30 min
- Treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen:
- 120mg/m² IV infusion on days 1 and 2 of 21-day cycle repeated for up to 8 cycles
- Infuse over 60 min
Injection:
- 25mg/vial
- 100mg/vial
Each formulation vial is intended for single dose only
Alkylating agent anticancer
It cross-links DNA strands resulting in DNA breakdown
- Lymphopenia
- Neutropenia
- Nausea
- Leukopenia
- Fatigue
- Fever
- Vomiting
- Diarrhea
- Thrombocytopenia
- Elevated bilirubin
- Constipation
- Cough
- Weight loss
- Anorexia
- Rash
- Anemia
- Headache
- Rigors
- Asthenia
- Dyspnea
- Stomatitis
- Back pain
- Dehydration
- Dizziness
- Abdominal pain
- Peripheral edema
- Insomnia
- Infection
- Dyspepsia
- Pruritus
- GERD
- Hypersensitivity to bendamustine or mannitol
- Atrial fibrillation
- Congestive heart failure (some fatal)
- Myocardial infarction (some fatal)
- Palpitation
- Pregnancy 1st trimester
- Breastfeeding during treatment and for at least 1 week after discontinuation
- CrCl <30
- Live bacterial vaccines
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Bemustar | 100mg | Injection | 1’s | Atlanta Biologicals | Synermed Pharma |
| Ribomustin | 25mg | Injection | 1’s | Astellas Pharma | Harley’s Ltd |
| Ribomustin | 100mg | Injection | 5’s | Astellas Pharma | Harley’s Ltd |